HC Wainwright Has Negative Outlook for DYN FY2024 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – HC Wainwright dropped their FY2024 EPS estimates for shares of Dyne Therapeutics in a report released on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($3.55) for the year, down from their previous forecast of ($3.06). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.39) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2024 earnings at ($1.04) EPS, FY2025 earnings at ($3.35) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at $0.19 EPS.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25).

Several other analysts have also recently weighed in on the stock. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Piper Sandler reiterated an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Stifel Nicolaus raised their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $29.34 on Monday. Dyne Therapeutics has a 1 year low of $10.03 and a 1 year high of $47.45. The stock has a market capitalization of $2.99 billion, a PE ratio of -8.24 and a beta of 1.10. The stock has a 50-day simple moving average of $32.42 and a 200-day simple moving average of $35.26.

Insider Activity

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 782 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the sale, the director now owns 15,962 shares of the company’s stock, valued at $528,342.20. This trade represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 176,257 shares of company stock valued at $6,193,718. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. FMR LLC lifted its holdings in shares of Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after purchasing an additional 3,707,734 shares during the period. RTW Investments LP raised its position in Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after buying an additional 431,503 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after acquiring an additional 2,189,339 shares during the period. RA Capital Management L.P. boosted its holdings in shares of Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after acquiring an additional 440,890 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.